Recent developments in the treatment of sexually transmitted diseases.
Recent changes in the treatment of sexually transmitted diseases include recognition of penicillin-resistant Neisseria gonorrhoeae, identification of Chlamydia trachomatis as the leading cause of bacterial genital infection in the United States, and the realization that the urethritis syndrome is often associated with multiple pathogens. There is currently no monotherapy that eradicates all STD pathogens. The role of fluoroquinolones in the treatment of STDs is still evolving. The investigational agent, temafloxacin, has good activity against gonococci, nongonococcal organisms, and, unlike other quinolones, against Bacteroides fragilis and other anaerobes. Norfloxacin, ciprofloxacin, enoxacin, ofloxacin, and temafloxacin single-dose therapy have demonstrated clinical efficacy for gonococcal infections in non-comparative and comparative trials, including bacterial eradication of isolates resistant to other agents.
Mogabgab
W J
WJ
Department of Medicine, Tulane University, New Orleans, Louisiana 70112.
D042462:4-Quinolones; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D006069:Gonorrhea / Q000188:drug therapy; D006801:Humans; D015231:Sexually Transmitted Diseases, Bacterial / Q000188:drug therapy*
D042462:4-Quinolones; D000890:Anti-Infective Agents